Developer docs
API playgroundTry for free, no card

Search company profiles

Repairon

Full company profile

uuid0004ti1

Namestring
Repairon
Legal namestring
Repairon GmbH
Websiteurl
repairon.de
Company typeenum
Private
Founded yearint
2014
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGöttingen, Germany
HQ citystring
Göttingen
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative heart therapy, engineered heart muscle, iPSC tissue engineering, cardiac cell therapy, biological ventricular assist
Industry5 codes
1Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
CodeHLAAAGABPrimaryYes
2Stem Cell–Based Regenerative Therapies
CodeHLAAAGAAPrimaryNo
3Stem Cell Therapies (MSC/iPSC/HSC-derived)
CodeHLAAABAEPrimaryNo
4Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
CodeHLAHAFALPrimaryNo
5Heart Failure & Transplant Cardiology
CodeHLAKABADPrimaryNo
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Regenerative Medicine
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1EHM Patch Therapy (Future Commercial)
TypeOne Time License
Description

Repairon is a clinical-stage biotech company developing regenerative heart failure therapy. No commercial revenue currently; all products are in clinical development. The company aims to commercialize EHM patches as off-the-shelf allogeneic products for advanced heart failure patients.

repairon.de
2Licensing and IP
TypeLicensing Royalties
Description

Company commercializes tissue engineered products based on licensed intellectual property from Prof. Zimmermann's research. Core-IP and additional IP licensed to secure freedom to operate for commercial product development.

repairon.de
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Repairon develops, manufactures, and plans to commercialize induced pluripotent stem cell (iPSC)-based Engineered Heart Muscle (EHM) — also branded as BioVAT (Biological Ventricular Assist Tissue) — for the treatment of patients with advanced heart failure. The core product is delivered as EHM Patches (40x40x1 mm collagen-based tissue patches with 40 million cardiomyocytes and stromal cells, scalable up to 20 EHM = 800 million cells) for locally targeted heart repair, or as EHM Pouches for support of enlarged, functionally impaired hearts such as in dilated cardiomyopathy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Left ventricular ejection fraction increased 6.9% at 12 months in patients at maximum safe dose
+4 more records
Product overview1 text field

Repairon is a German biotech company developing iPSC-based tissue engineering products for organ repair. Its core product is Engineered Heart Muscle (EHM), also referred to as BioVAT (Biological Ventricular Assist Tissue), which consists of self-contracting heart tissue patches derived from induced pluripotent stem cells. The first-generation product is delivered as EHM Patches for locally targeted heart repair in ischemic heart failure or as EHM Pouches for dilated cardiomyopathy. Second-generation products include hypo-immune EHM to eliminate immunosuppression needs and EHM with co-delivery capability for local delivery of pharmacologically active proteins or nucleotides.

Product and service1 record
1Engineered Heart Muscle (EHM)
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1University Medical Center Göttingen (UMG)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Strong strategic partnership established in 2017 for clinical development. Prof. Zimmermann serves as Director of Institute of Pharmacology and Toxicology at UMG. UMG is sponsor of BioVAT-HF clinical trial. Collaboration enables preclinical characterization through clinical development.

2German Center for Cardiovascular Research (DZHK)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Public/private partnership with German Center for Cardiovascular Research supporting BioVAT-HF clinical trial. DZHK provides research infrastructure and funding support for cardiovascular research initiatives.

repairon.de
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Heartseed Inc.
TypeDirect peer
Description

Japanese clinical-stage biotech developing HS-001, an iPSC-derived ventricular cardiomyocyte cell therapy for advanced heart failure. Most analogous peer: same iPSC-cardiomyocyte mechanism, same advanced HF indication, similar clinical-stage maturity.

2Athersys
TypeDirect peer
Description

Clinical-stage cell therapy company developing MultiStem (multipotent adult progenitor cells) for cardiovascular indications including acute myocardial infarction and heart failure. Competes on the same regenerative mechanism for cardiac indications with a different allogeneic cell platform.

3Help Therapeutics
TypeDirect peer
Description

Chinese clinical-stage biotech developing HiCM-188, an iPSC-derived cardiomyocyte patch for heart failure. Closest technology peer: builds allogeneic iPSC-cardiomyocyte tissue patches for cardiac remuscularization, directly competing for the same patient population.

4Tenaya Therapeutics
TypeEmerging player
Description

Clinical-stage biotech developing both gene therapy (TN-201) and iPSC-based regenerative approaches for inherited and adult cardiomyopathies. Comparable on the iPSC platform side and on treating HFrEF patients, though predominantly a gene therapy program today.

5Capricor Therapeutics
TypeDirect peer
Description

Clinical-stage biotech developing CAP-1002, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy-associated cardiomyopathy and adult heart failure. Competes directly for advanced HF patients using a non-iPSC cell source.

6BioCardia
TypeDirect peer
Description

Clinical-stage developer of the Helix transendocardial delivery system and cell therapy programs (BCDA-01, BCDA-02) for heart failure. Direct peer on the cardiac cell delivery/monitoring side, addressing the same advanced HF patient with delivery-tech overlap.

7Mesoblast
TypeDirect peer
Description

Commercial-stage cell therapy company whose REVASCOR (rexlemestrocel-L) allogeneic mesenchymal precursor cell product targets advanced heart failure with reduced ejection fraction. Direct competitor at the indication level with a different cell type but same target patient and remodeling mechanism.

8CellProthera
TypeEmerging player
Description

French clinical-stage biotech developing Protheracytes — autologous CD34+ stem cell therapy for post-MI heart failure and critical limb ischemia. Adjacent cell therapy competitor targeting similar ischemic HF patient population with an autologous (rather than allogeneic) manufacturing model.

9Bristol-Myers Squibb
TypeBroad incumbent
Description

Large pharmaceutical incumbent with cardiac and cell therapy ambitions via the Juno/Celgene acquisitions (CEO Germeroth's prior firm). Sets the partnership/M&A benchmark for cardiac cell therapy assets and is a plausible strategic acquirer as a leader in cardiac medicine.

10Lexeo Therapeutics
TypeEmerging player
Description

Clinical-stage AAV gene therapy company with cardiac programs (LX2001 for Friedreich ataxia cardiomyopathy and LX2020 for HFrEF). Competes for the same advanced HFrEF patient with a non-cell mechanism; reflects alternative approaches Repairon will be benchmarked against.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Repairon

Regenerative Medicinerepairon.de

Repairon firmographics

Firmographics
Name
Repairon
Legal name
Repairon GmbH
Website
https://repairon.de
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Repairon industry classification

Industry
Product category
Regenerative Medicine
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)
akta.pro secondary industries
Stem Cell–Based Regenerative Therapies (HLAAAGAA), Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL), Heart Failure & Transplant Cardiology (HLAKABAD)

Keywords

  • Regenerative heart therapy
  • Engineered heart muscle
  • IPSC tissue engineering
  • Cardiac cell therapy
  • Biological ventricular assist

Where Repairon is headquartered

Location

Headquarters

HQ city
Göttingen
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

Repairon business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. EHM Patch Therapy (Future Commercial): Repairon is a clinical-stage biotech company developing regenerative heart failure therapy. No commercial revenue currently; all products are in clinical development. The company aims to commercialize EHM patches as off-the-shelf allogeneic products for advanced heart failure patients.
  2. Licensing and IP: Company commercializes tissue engineered products based on licensed intellectual property from Prof. Zimmermann's research. Core-IP and additional IP licensed to secure freedom to operate for commercial product development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Repairon product offering

Product offering

Core offering

Repairon develops, manufactures, and plans to commercialize induced pluripotent stem cell (iPSC)-based Engineered Heart Muscle (EHM) — also branded as BioVAT (Biological Ventricular Assist Tissue) — for the treatment of patients with advanced heart failure. The core product is delivered as EHM Patches (40x40x1 mm collagen-based tissue patches with 40 million cardiomyocytes and stromal cells, scalable up to 20 EHM = 800 million cells) for locally targeted heart repair, or as EHM Pouches for support of enlarged, functionally impaired hearts such as in dilated cardiomyopathy.

Product overview

Repairon is a German biotech company developing iPSC-based tissue engineering products for organ repair. Its core product is Engineered Heart Muscle (EHM), also referred to as BioVAT (Biological Ventricular Assist Tissue), which consists of self-contracting heart tissue patches derived from induced pluripotent stem cells. The first-generation product is delivered as EHM Patches for locally targeted heart repair in ischemic heart failure or as EHM Pouches for dilated cardiomyopathy. Second-generation products include hypo-immune EHM to eliminate immunosuppression needs and EHM with co-delivery capability for local delivery of pharmacologically active proteins or nucleotides.

Differentiator

Problem solved

Functional benefit

Products and services

  • Engineered Heart Muscle (EHM)

Quantifiable outcome

  • Left ventricular ejection fraction increased 6.9% at 12 months in patients at maximum safe dose
  • +4 more outcomes

Companies that use Repairon

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Repairon technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Repairon partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • University Medical Center Göttingen (UMG)coreStrategic or Co-development Partner · 1 January 2017Strong strategic partnership established in 2017 for clinical development. Prof. Zimmermann serves as Director of Institute of Pharmacology and Toxicology at UMG. UMG is sponsor of BioVAT-HF clinical trial. Collaboration enables preclinical characterization through clinical development.
  • German Center for Cardiovascular Research (DZHK)coreStrategic or Co-development PartnerPublic/private partnership with German Center for Cardiovascular Research supporting BioVAT-HF clinical trial. DZHK provides research infrastructure and funding support for cardiovascular research initiatives.

Scale indicators7 records

Recent moves7 records

Expansion highlights4 records

Repairon competitors and assessment

Company assessment

Direct peers

  • Heartseed Inc. Japanese clinical-stage biotech developing HS-001, an iPSC-derived ventricular cardiomyocyte cell therapy for advanced heart failure. Most analogous peer: same iPSC-cardiomyocyte mechanism, same advanced HF indication, similar clinical-stage maturity.
  • Athersys: Clinical-stage cell therapy company developing MultiStem (multipotent adult progenitor cells) for cardiovascular indications including acute myocardial infarction and heart failure. Competes on the same regenerative mechanism for cardiac indications with a different allogeneic cell platform.
  • Help Therapeutics: Chinese clinical-stage biotech developing HiCM-188, an iPSC-derived cardiomyocyte patch for heart failure. Closest technology peer: builds allogeneic iPSC-cardiomyocyte tissue patches for cardiac remuscularization, directly competing for the same patient population.
  • Capricor Therapeutics: Clinical-stage biotech developing CAP-1002, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy-associated cardiomyopathy and adult heart failure. Competes directly for advanced HF patients using a non-iPSC cell source.
  • BioCardia: Clinical-stage developer of the Helix transendocardial delivery system and cell therapy programs (BCDA-01, BCDA-02) for heart failure. Direct peer on the cardiac cell delivery/monitoring side, addressing the same advanced HF patient with delivery-tech overlap.
  • Mesoblast: Commercial-stage cell therapy company whose REVASCOR (rexlemestrocel-L) allogeneic mesenchymal precursor cell product targets advanced heart failure with reduced ejection fraction. Direct competitor at the indication level with a different cell type but same target patient and remodeling mechanism.

Emerging players

  • Tenaya Therapeutics: Clinical-stage biotech developing both gene therapy (TN-201) and iPSC-based regenerative approaches for inherited and adult cardiomyopathies. Comparable on the iPSC platform side and on treating HFrEF patients, though predominantly a gene therapy program today.
  • CellProthera: French clinical-stage biotech developing Protheracytes — autologous CD34+ stem cell therapy for post-MI heart failure and critical limb ischemia. Adjacent cell therapy competitor targeting similar ischemic HF patient population with an autologous (rather than allogeneic) manufacturing model.
  • Lexeo Therapeutics: Clinical-stage AAV gene therapy company with cardiac programs (LX2001 for Friedreich ataxia cardiomyopathy and LX2020 for HFrEF). Competes for the same advanced HFrEF patient with a non-cell mechanism; reflects alternative approaches Repairon will be benchmarked against.

Broad incumbents

  • Bristol-Myers Squibb: Large pharmaceutical incumbent with cardiac and cell therapy ambitions via the Juno/Celgene acquisitions (CEO Germeroth's prior firm). Sets the partnership/M&A benchmark for cardiac cell therapy assets and is a plausible strategic acquirer as a leader in cardiac medicine.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights8 records

Customer concentration

Repairon social profiles

Digital presence

Repairon financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Repairon leadership team

Management profile

Number of profiles

Profiles8 records

Repairon funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Repairon M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Repairon

What does Repairon do?

Repairon develops, manufactures, and plans to commercialize induced pluripotent stem cell (iPSC)-based Engineered Heart Muscle (EHM) — also branded as BioVAT (Biological Ventricular Assist Tissue) — for the treatment of patients with advanced heart failure. The core product is delivered as EHM Patches (40x40x1 mm collagen-based tissue patches with 40 million cardiomyocytes and stromal cells, scalable up to 20 EHM = 800 million cells) for locally targeted heart repair, or as EHM Pouches for support of enlarged, functionally impaired hearts such as in dilated cardiomyopathy.

Is Repairon a public or private company?

Repairon is a private company. It is classified as venture growth investor backed and is currently operating.

When was Repairon founded?

Repairon was founded in 2014. It employs 11 to 50 people.

Where is Repairon based?

Repairon is headquartered in Göttingen, Germany, in the Europe region.

How does Repairon make money?

Two revenue lines are on record. EHM Patch Therapy (Future Commercial) is the primary driver. The others are licensing and IP.

Who are Repairon's main competitors?

Direct peers on record are Heartseed Inc., Athersys, Help Therapeutics, Capricor Therapeutics, BioCardia and Mesoblast. Emerging players are Tenaya Therapeutics, CellProthera and Lexeo Therapeutics. Bristol-Myers Squibb is listed as a broad incumbent.

Does Repairon have an API?

No public API is recorded for Repairon.

What industry is Repairon in?

Repairon's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 325414 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireWegweisende Therapie bei fortgeschrittener Herzinsuffizienz: Ergebnisse der klinischen Studie BIOVAT-HF im NEJM veröffentlichtRepairon, a German biotech company, announced that results from its BioVAT-HF clinical trial evaluating stem-cell-derived heart muscle patches for advanced heart failure patients were published in the New England Journal of Medicine; the Phase I–II trial involving 20 patients (16 at maximum safe dose) demonstrated feasibility of restoring heart muscle function, with patients showing increased left ventricular ejection fraction (+6.9%), thickened heart wall (+2.9 mm at 12 months), and improved quality-of-life scores (+15 KCCQ-OSS points at 12 months). Three patients died from causes deemed unrelated to the BioVAT implant, and serious adverse events were primarily linked to pre-existing conditions and immunosuppression; no ventricular fibrillation occurred. The authors conclude that further clinical investigation with longer follow-up periods is required before the therapy can advance toward regulatory approval.GlobeNewswireRepairon annonce la publication dans le NEJM des résultats de l’essai clinique BIOVAT-HF, une thérapie innovante pour l’insuffisance cardiaque avancéeRepairon, a German biotechnology company, announced the publication in the New England Journal of Medicine of results from its Phase I-II BioVAT-HF clinical trial, evaluating an artificial human cardiac muscle tissue graft in 20 patients with advanced heart failure. The trial demonstrated measurable improvements in left ventricular ejection fraction (up to 6.9%), cardiac wall thickness, and quality-of-life scores, with histological analysis of one explanted heart providing direct evidence of human heart remuscularization. The authors concluded that additional clinical studies with extended follow-up are warranted to further validate the therapeutic approach.GlobeNewswireGroundbreaking therapy for advanced heart failure: Outcomes of the BIOVAT-HF clinical trial published in NEJMRepairon, a German biotech company, announced that clinical trial results for its engineered heart muscle tissue patch (BioVAT-HF) have been published in the New England Journal of Medicine, reporting that patients with advanced heart failure showed improved heart muscle function, with left ventricular ejection fraction increasing 6.9% and quality of life scores rising 15 points at 12 months among the 16 patients who received the safe maximum dose. The Phase 1-2 trial enrolled 20 patients, with 3 deaths during the study attributed to causes deemed unrelated to the BioVAT treatment by the Data Safety Monitoring Board. The authors concluded that further clinical investigations with longer follow-up are warranted to confirm the therapeutic potential of myocardial regeneration.The Canadian Press NewsScientists Reveal Ancient Coral Habitats and Deep-Sea Canyons off Newfoundland and Labrador CoastOceana Canada and Fisheries and Oceans Canada conducted a joint expedition to the Southern Newfoundland Slope in July and October 2025, documenting ancient coral forests, sea pen fields, and deep-sea habitats. The findings, including species like halibut and cod, will be presented at a June 2, 2026 gathering in Ottawa. New insights are expected as data analysis continues.GlobeNewswireGroundbreaking therapy for advanced heart failureRepairon GmbH formed its US subsidiary Repairon USA to expand clinical trials and pursue regulatory approval for its heart failure therapy. A Phase 2 interim analysis showed improved heart wall thickness and function in advanced HF patients. The company plans US trials upon FDA authorization.FinSMEsRepairon Closes Series A FinancingRepairon, a Göttingen-based biotech, raised an undisclosed amount in Series A financing led by Bioventure Management GmbH and Satorius AG. The funds will support further clinical development of its regenerative heart failure therapy, with its lead candidate in a Phase 2 trial.PR NewswireGroundbreaking Therapy for Advanced Heart Failure: Repairon Completes Series A Financing to Expand the Clinical Development of Its Regenerative Heart TherapyGerman biotech company Repairon GmbH has completed a Series A financing round led by Bioventure Management GmbH and Satorius AG to advance its regenerative heart failure therapy, which uses lab-engineered cardiac cell sheets to repair damaged ventricles. The funding will support the transition to a European Phase 3 registration trial and scale GMP production, with the therapy currently in a Phase 1/2 clinical study in Germany where interim analysis recruitment has completed. The therapy aims to address advanced heart failure, which currently has limited treatment options beyond mechanical pumps or transplantation.GlobeNewswireBioVAT-HF Phase 1/2 Reveals First Evidence for Effective Heart Repair in Advanced Heart FailureRepairon and partners presented BioVAT-HF Phase 1/2 trial data at the AHA Scientific Sessions, showing Engineered Human Myocardium grafts were safe and well-tolerated at all tested doses. The trial provided first evidence of improved heart function and symptoms six to twelve months after implantation.GlobeNewswireRepairon Appoints Co-Founder Dr. Lothar Germeroth as ChiefRepairon appointed Dr. Lothar Germeroth, co-founder and executive chairman, as CEO, retaining his chairman role. The company's lead asset, engineered heart muscle, is in a Phase 1/2 trial showing safety and early signs of improved heart function. Interim data on the highest tested dose is expected in Q2/Q3 2024.GlobeNewswireRepairon Announces Completion of Dose-Finding Part of BioVAT-HF Phase 1/2 Trial in Advanced Heart FailureRepairon and partners completed the dose-finding cohort of the BioVAT-HF Phase 1/2 trial, enrolling 10 patients with increasing iPSC-derived cardiomyocyte doses. The safe maximal dose of 800 million cells was identified, with interim data on 15 patients expected in Q2 2024. Completion of the trial with 35 patients is expected in H2 2025.